CTEV · Claritev Corp · Documents

$26.82 -0.08 (-0.30%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$457.95M

17.07M

Volume · Nov 13 175.35K Avg daily vol (3M) 202.02K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $965.41M up 3.7% 10-K filed Feb 26, 2026 Quarterly report New FY2026 Q3 Revenue $268.31M up 9.1% 10-Q filed Nov 9, 2026 Latest results Financial results 8-K filed Aug 7, 2026 Earnings call New Q3 2026 earnings call Held Nov 9, 2026

2026

Nov 9

Earnings call

Full-year guidance raised; 2027 revenue expected at least $1.1 billion

Claritev Corporation raised full-year revenue guidance to $1.038 billion to $1.043 billion and adjusted EBITDA guidance to $625 to $630 million, while expecting at least $1.1 billion of revenue in 2027.

4 source passages

We're raising our full-year revenue guidance to a new range of $1.038 billion to $1.043 billion, a $30.5 million increase at the midpoint from our previous guidance. We are raising our full-year adjusted EBITDA guidance to $625 to $630 million, an increase of $12.5 million at the midpoint. We now expect to achieve at least $1.1 billion of revenue in 2027, driven by our strong performance this year, continued momentum in ACV bookings, and the ability of our growth and operation teams to translate those bookings into revenue. Thank you for standing by, and welcome to the Claritev Corporation 3rd Quarter 2026 Earnings Conference Call. Open the document at this passage

Nov 9

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Revenue rises while IT control weaknesses persist

Claritev reported revenue increased $22.4 million, or 9.1%, for the three months ended September 30, 2026, while operating income rose 104.9% to 20,627 (in thousands). IT general-control material weaknesses remained unremediated, leaving disclosure controls ineffective.

Revenue $268.31M ▲ 9.1% Net loss $61.78M Diluted EPS -$3.64

Read from the MD&A section

5 source passages

Revenues increased by $22.4 million, or 9.1%, for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. Operating income | 20,627 | 10,067 | 10,560 | 104.9% The Company, primarily through its operating subsidiary, Multiplan, Inc., d/b/a Claritev, offers its solutions nationally through a range of solution lines, which include: As of December 31, 2025, the Company identified material weaknesses over certain information technology ("IT") general controls that were disclosed in Part II, Item 9A of the Company’s Form 10-K, which remained unremediated as of September 30, 2026. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that, as of September 30, 2026, as a result of the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective to provide reasonable assurance that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Open the document at this passage

Nov 9

Current report 8-K

Claritev raises 2026 outlook as Q3 revenue grows

Claritev Corporation reported Q3 2026 revenues of $268.3 million, up 9.1%, and a net loss of $61.8 million, while raising 2026 revenue guidance to $1.038 billion to $1.043 billion. It also introduced preliminary 2027 revenue expectations of $1.1 billion.

6 source passages

Revenues of $268.3 million for Q3 2026, an increase of 9.1%, compared to revenues of $246.0 million for Q3 2025. Net loss of $61.8 million for Q3 2026, compared to net loss of $69.8 million for Q3 2025. Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the third quarter ended September 30, 2026. With increasing top-line momentum, we intend to continue investing in innovation and growth, while maintaining our focus on profitability and improving free cash flow conversion. Revenues | $1 billion to $1.02 billion | $1.038 billion to $1.043 billion We are now running approximately a year ahead of our March 2026 Investor Day plan, with preliminary 2027 revenue expectations of $1.1 billion. Open the document at this passage

Oct 15

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Claritev Corporation appointed Jennifer Main as a Class II director and Audit Committee member on October 15, 2026, filling a newly created seat; Jason Kap ceased serving on the Audit Committee.

Sep 15

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

Sep 15

Current report 8-K Events of Sep 14

Director or officer change, or executive pay, Regulation FD disclosure AI summary on its way

Aug 11

Investor event

Canaccord Genuity's 46th Annual Growth Conference AI summary on its way

Aug 7

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way